Factor Information
Data ID 2703
Factor mPAP (mean pulmonary artery pressure)
Description For mean pulmonary artery pressure, significant reduction was only observed in the VSD group.
Biomarker NA
Classification E10 (physiological factor - other)
Association
Application prognosis
Objective The potential effect of sildenafil on pulmonary arterial hypertension related to CHD may be associated with shunt location.
p Value <0.001
Conclusion For mean pulmonary artery pressure, significant reduction was only observed in the VSD group.
Risk Factor unknown
CHD Type
ID 484
CHD Type isolated CHD
CHD Subtype ASD/VSD/PDA
Reference
PMID 21678455
Year 2011
Title The efficacy and safety of sildenafil in patients with pulmonary arterial hypertension associated with the different types of congenital heart disease
Sample
Population adults
Source 12-week, prospective, open label, multicenter trial
Region Beijing, China
Method 12-week, prospective, open label, multicenter trial
Race Asian
Disease History N/A
Treatment History N/A
Group VSD (12 Weeks)(Treatment) VSD (Baseline)(Control)
Number 24 24
Age 26.58 ± 9.61 years 26.58 ± 9.61 years
Gender (Male: Female) 08:16:00.000 08:16:00.000
Marker Level 86.32 ± 19.93 mm Hg 76.58 ± 16.81 mm Hg